Bin (Jason) Zhang

Extensive scientific and managerial experience in oncology drug discovery and therapeutic biomarker identification with successful track record of pre-clinical candidate (PCC) delivery. Highly motivated and self-directed project manager with demonstrated success in managing early stage (lead identification and optimization) drug discovery projects. Participated in multiple integrated drug discovery programs from hits to leads through PCC selection of anti-cancer agents including targeted therapies, radiation therapy sensitizer, immunotherapies, etc, which target receptor tyrosine kinases (RTKs), non-receptor tyrosine kinases (nRTKs), MAPK pathway, PI3K/AKT/mTOR pathway, hedgehog pathway, Notch pathway, WNT pathway, nuclear receptors, DNA repair modulators, epigenetics regulators, ubiquitin-proteasome system, tumor-specific antigens, immune checkpoint proteins and other signaling molecules/pathways. Demonstrated expertise in in vivo cancer models, including cell line-derived xenograft (CDX) models, patient-derived xenograft (PDX) models, syngeneic models, humanized models for the evaluation of small molecules and biologics. Specialities: -Oncology drug discovery -Integrated anti-cancer drug discovery programs -Preclinical drug develop -Project management -In vivo cancer pharmacology -Biomarker and translational research -Patient-derived xenograft (PDX) model -Genetic characterization of PDX model -Cell line-derived xenograft (CDX) model -Syngeneic tumor model -Humanized mouse model -Orthotopic xenograft model -Metastatic tumor model -Resistant cancer model -Pharmacokinetics (PK) and pharmacodynamics (PD) -Cell-based assay development -Tumor chemosensitivity assay (TCA) -Cell line establishment -Cancer stem cell (CSC) culture and identification -Enzymatic assay development -High-throughput screening